Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.


Download subscription form here



Latest News !

Dr Boreham's Crucible: Antisense Therapeutics

Opthea Jumps 160% on OPT-302 Wet AMD Result

Victoria Innovation Minister Martin Pakula Talks Biotech

Bionomics BNC210 Fails 2nd Phase II Trial (Agitation)

Ausbiotech: 'Threat To R&D Incentive Worries Sector'

Minister Karen Andrews Talks Biotech

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Actinogen: 'Xanamem Fails Alzheimer's Endpoints'; Falls 71%




August BDI-40 Up 13%, Big Caps Up 3%,
ASX200 Down 3%, NBI Down 3%

BDI-40 A '10-Bagger' Since Global Financial Crisis

 Opthea Up 341%, Polynovo 31%, Neuren 24%, Pro Medicus 21%;
Osprey Down 32%, Clinuvel 21%, Uscome 21%, Pharmaxis 18%


September 1, 2019

The graphs below tell it all. 

The adjusted Biotech Daily Top 40 Index (BDI-40) is at a record high, and since the Global Financial Crisis all-time low, is just shy of a “10-bagger”, up from $2,087 million at December 31, 2008, to an adjusted $18,413 million on Friday.
The unadjusted BDI-40 was up 13.1 percent in August, to a collective market capitalization of $14,288 million, the AX200 retreated 3.1 percent to 6,604 points, while the Nasdaq Biotechnology Index (NBI) fell a further 2.6 percent.
In August, the collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) was up 3.2 percent to a record $148,614 million, despite Cochlear slipping 3.1 percent to $12,325 million. Resmed was up 8.6 percent to $29,579 million and CSL was up 2.6 percent to $106,710 million.
While 24 of the BDI-40 stocks fell, with just 11 up and five unchanged, the falls were mostly in the much smaller Second 20.
The Top 20 boasts four companies worth more than $1 billion each (see last page), including Pro Medicus at $3.8 billion, along with Avita, Mesoblast and Opthea most of the way to $1 billion each.
Opthea was the clear percentage best, on positive phase II Wet AMD trial results (BD: Aug 7, 2019), up 340.5 percent and adding $647 million to its market capitalization, but Pro Medicus added $654 million to the indices.
Polynovo quietly rose $330 million in August, up 31.2 percent to $1,388 million, followed by Neuren (24.2%), Pro Medicus (20.5%), Nanosonics (up $258m; 15.6%), Resonance (14.6%) and Immutep (14.1%).
Osprey continued to struggle, down just $10 million but 32.3 percent to $21 million. Clinuvel retreated $340 million or 21.4 percent to $1,252 million on the terrible news that its revenue was only up 22 percent to a record $31 million, with a record net profit after tax up 37 percent to $18 million - and it paid a dividend. That’s not very biotechy, is it?
Uscom also fell on good end-of-year news, down 21.1 percent to $15 million, followed by Pharmaxis (18%), Optiscan (16.7%), Next Science (16.4%), Starpharma (16.4%), Medical Developments (16.3%), Imugene (15.6%) and Proteomics (12.0%).
Cannabis Corner lost $300 million or 15.7 percent to $1,613 million, with 13 of the 18 falling, two unchanged and just three higher. Elixinol lost $169 million or 36.9 percent.
In the US, Queensland’s Protagonist jumped 34.7 percent to $508 million, Israel’s Redhill with Australian assets was up 16.4 percent to $319 million, Eyepoint (Psivida) was up 10.2 percent to $237 million, with Vaxart (Biota) up 6.25 percent to $17 million.
Outside the BDI-40, Painchek was up 523.3 percent from $30 million a year ago to $187 million, Alcidion climbed 321.2 percent for the year, Bluechiip put on 64.2 percent to $87 million in August, Mach7 passed the $100 million barrier and Mayne Pharma continued its slide, down 15.1 percent to $712 million for the month and 61.7 percent for the year.
BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2019 
3-Year Big Caps (Cochlear, CSL, Resmed) to Aug 31, 2019

BDI-40 ($m) v S&P ASX200 – Year to Aug 31, 2019 (current, raw data)



 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Aug 31, 2019


* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Cynata, Mesoblast
   Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: